drugset / Trial / NCT02794740

Study of X0002 Following Escalating Single and Multiple Doses Administered as Topical Application in Healthy Volunteers

NCT02794740

Phase 1 Completed 34 enrolled Tianjin XinChen-Techfields Pharma Co., LTD.
RandomizedParallel-groupTriple-blindTreatment

Summary

Primary Objectives: To evaluate the safety and tolerability of escalating single and multiple doses of X0002 administered as a topical application. Secondary Objectives: To characterize the single and and multiple pharmacokinetics of escalating doses of X0002 and its active metabolite ibuprofen as a topical application.

Timeline

Start
2016-06
Primary completion
2017-03
Completion
2017-03-29

Drugs

EvaluationDrugModalityDoseRoute
Subject IBUPROFEN TRELAMINE Small molecule Topical

Indications